医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BASF and Colorcon Cooperate on Kollicoat® IR for Ready-to-Use Pharmaceutical Coating Solutions

2014年10月08日 PM04:00
このエントリーをはてなブックマークに追加


 

HARLEYSVILLE, Pa. & LUDWIGSHAFEN, Germany

Colorcon, Inc. and BASF announce their cooperation for using immediate release coating polymer Kollicoat® IR for Colorcon’s fully formulated ready-to-use coatings.

Colorcon will expand their PVA-based product portfolio by offering customers an alternative efficient and convenient solution for the immediate release coating of pharmaceuticals and dietary supplements. “With this new ready-to-use coating option formulators can benefit from both the coating performance of Kollicoat IR and Colorcon’s worldwide unique, customized services”, said Daniele Piergentili, Vice President Global Marketing Pharma Ingredients at BASF.

“Kollicoat IR provides Colorcon with the capability to further expand our film coating portfolio, bringing more choice to our customers while providing customized solutions. We are pleased to cooperate with BASF to bring Kollicoat IR to a wider market, combining BASF’s polymer expertise with Colorcon’s knowledge of formulated film coating systems and our global reach,” said Cornelis van den Muyzenberg, VP of Sales and Business Development at Colorcon.

Adding Kollicoat IR as an alternative for use in targeted Opadry® complete film coating systems expands the cooperation between Colorcon and BASF.

Kollicoat IR, an ethylene glycol and vinyl alcohol graft copolymer, is BASF’s highly versatile and safe-in-use instant release coating polymer. This polymer enables processing at low temperatures and high solids content while delivering appropriate coating results.

Kollicoat is monographed in all major markets, and has furthermore received GRAS status (Generally Regarded As Safe) in the US and the European E-Number (E1209) for application in dietary – nutritional supplements.

About Colorcon

Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations.

About BASF

At BASF, we create chemistry – and have been doing so for 150 years. Our portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. As the world’s leading chemical company, we combine economic success with environmental protection and social responsibility. Through science and innovation, we enable our customers in nearly every industry to meet the current and future needs of society. Our products and solutions contribute to conserving resources, ensuring nutrition and improving quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF had sales of about €74 billion in 2013 and over 112,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.

Opadry® is a trademark of BPSI Holdings LLC.

CONTACT

Deborah Taylor
Global Market Communications Manager
dtaylor@colorcon.com
+44
1322 627234
or
Andres-Christian Orthofer
Global
Communication Nutrition & Health
andres-christian.orthofer@basf.com
+49
621 60-20173

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表